Progression-free survival (PFS)
The median follow-up for PFS was 10.2 months for the saracatinib/AI group (IQR 4.8–21.8 months) and 16.0 months (IQR 9.4–24.9 months) for the placebo/AI group (Fig. Progression-free survival in treatment arms (